Konstantinos Leventakos

6PUBLICATIONS
79CO-AUTHORS
Molecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Jul 27, 2026
The genomic landscape and treatment outcomes associated with CDKN2A/MTAP loss in patients with non-small cell lung cancer.

|May 20, 2026
Cellular Therapies in Solid Tumors: Are We Ready for Primetime?

|May 07, 2025
JAB-3312, a Potent Allosteric SHP2 Inhibitor That Enhances the Efficacy of RTK/RAS/MAPK and PD-1 Blockade Therapies.

Di Kang, Yanping Wang, Yiwei Lin

|Feb 03, 2025
Evolving Field of Immunotherapy: Pioneering New Paths in Small-Cell Lung Cancer.

Antonious Ziad Hazim, Konstantinos Leventakos, Vinicius Ernani

|Aug 08, 2023
MRTX1719 Is an MTA-Cooperative PRMT5 Inhibitor That Exhibits Synthetic Lethality in Preclinical Models and Patients with MTAP-Deleted Cancer.

Lars D Engstrom, Ruth Aranda, Laura Waters

|Jun 06, 2023
Early Changes in Circulating Cell-Free KRAS G12C Predict Response to Adagrasib in KRAS Mutant Non-Small Cell Lung Cancer Patients.

Cloud P Paweletz, Grace A Heavey, Yanan Kuang

Pageof 1

Frequent Collaborators

2 joint publications

Antonious Ziad Hazim

2 joint publications

Jordi Rodon

2 joint publications

Melissa L Johnson

2 joint publications

Vinicius Ernani